Phase 1 N=46 Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine
Enteric Fever
Primary: Number of Participants With Treatment Emergent Adverse Events — 4; 9; 8; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=96 Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
Typhoid Fever
Primary: Number of Participants With Solicited Administration-site Events After the First Vaccination — 3; 11; 20; 22 Participants
N/A N=1,492 The Etiology of Acute Febrile Illness Requiring Hospitalization
Acute Febrile Illness
Primary: The Etiologies (Bacteria, Viruses, Parasites, Fungi and Others) of Fever Illness Expressed in Percentages of Enrolled Subjects. — 621; 362; 15; 5 Participants
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
N/A N=147 Trial of Rifaximin in the Treatment of Tropical Enteropathy
Tropical Enteropathy
Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc
Phase 2 N=200 Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
Typhoid Fever
Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 85; 100; 89 percentage of subjects
N/A N=23 Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose
ETEC Diarrhea
Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea
Phase 1 N=60 Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
N/A N=28 Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A
Healthy Volunteer
Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants
Phase 1 N=22 IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Cancer of the Liver · Liver Cancer · Hepatoma
Primary: Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium — 0; 0; 0; 0 Participants
N/A N=60 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Phase 2 N=155 A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
Salmonella Infections
Primary: Stage 1: Number of Participants With Any Solicited Administration Site Events After the First Study Intervention Administration — 1; 0; 0; 0 Participants
N/A N=1,046 Febrile Illness in Kinshasa and Kimpese
Febrile Illness
Primary: Proportion of Survival With Symptom Resolution — 96.9 percentage of participants
Phase 2 N=120 Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
Typhoid Fever
Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 100; 100; 11 percentage of subjects
Phase 2 N=187 Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Typhoid
Primary: Number and Proportion of Subjects Reporting Suspected Unexpected Serious Adverse Reactions. — 0; 0; 0; 0 Participants
Phase 2 N=475 Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
Escherichia Coli Diarrhea
Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants
N/A N=1,545 Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study
Infectious Gastroenteritis
Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants
Phase 2 N=120 Traveler's Diarrhea (TD) Automated Process
Prevention of Travelers' Diarrhea
Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer
Phase 2 N=60 Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
Diarrhea
Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events
Phase 3 N=700 Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Rotavirus Diarrhea · Vaccine Virus Shedding · Tropical Enteropathy
Primary: Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial) — 99; 109 Participants — p=0.4
Phase 2 N=113 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection
Shigellosis
Primary: Post-challenge Diarrhea, Fever, and Blood in Stool Adverse Events by Study Group — 1; 0; 4; 4 participants
Phase 2 N=9 A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization
Antibiotic Resistant Strain
Primary: Percentage of Participants With VRE Decolonization — 1; 1 Participants
Phase 1 N=50 Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
Typhoid Fever
Primary: Number of Subjects Reporting Any Post Immunization Reactions — 23; 16 participants
Phase 2 N=301 Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants
Typhoid Fever
Primary: Number of Infants With Adverse Reactions After Vaccination — 22; 24; 17; 7 participants
N/A N=93 Rapid Flu Tests in Travelers With Fever
Influenza
Primary: Cost for the Medical Management of Patients — 581; 661 USD
Phase 3 N=30 Efficacy of Rifaximin in Preventing Campylobacteriosis
Dysentery · Diarrhea · Enteric Campylobacteriosis
Primary: Campylobacteriosis — 13; 11 Participants
Phase 2 N=43 A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
Bacterial Enteritis
Primary: Bacterial Elimination Rate (BER) in the CDI and EI Groups — 100.0; 72.7; 90.0; 87.5 percentage of participants
Phase 1 N=16 Shigella WRSS1 Vaccine Trial in Bangladesh
Diarrhea
Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants